Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerPrimary Peritoneal Cavity Cancer
- Registration Number
- NCT00023699
- Lead Sponsor
- Gynecologic Oncology Group
- Brief Summary
- RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer or primary peritoneal cancer. 
 PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.
- Detailed Description
- OBJECTIVES: 
 * Determine the antitumor cytostatic activity of gefitinib, in terms of 6-month progression-free survival, in patients with persistent or recurrent ovarian epithelial or primary peritoneal carcinoma.
 * Determine the nature and degree of toxicity in patients treated with this drug.
 * Determine the partial and complete response rates in patients treated with this drug.
 * Determine the duration of progression-free and overall survival in patients treated with this drug.
 OUTLINE: This is a multicenter study.
 Patients receive oral gefitinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
 Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
 PROJECTED ACCRUAL: Approximately 22-60 patients will be accrued for this study within 1-2 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
- Name - Time - Method 
- Secondary Outcome Measures
- Name - Time - Method 
Trial Locations
- Locations (53)
- University of Alabama at Birmingham Comprehensive Cancer Center πΊπΈ- Birmingham, Alabama, United States - Jonsson Comprehensive Cancer Center, UCLA πΊπΈ- Los Angeles, California, United States - Community Hospital of Los Gatos πΊπΈ- Los Gatos, California, United States - Chao Family Comprehensive Cancer Center πΊπΈ- Orange, California, United States - University of Colorado Cancer Center πΊπΈ- Denver, Colorado, United States - Walter Reed Army Medical Center πΊπΈ- Washington, District of Columbia, United States - H. Lee Moffitt Cancer Center and Research Institute πΊπΈ- Tampa, Florida, United States - Rush-Presbyterian-St. Luke's Medical Center πΊπΈ- Chicago, Illinois, United States - University of Chicago Cancer Research Center πΊπΈ- Chicago, Illinois, United States - Indiana University Cancer Center πΊπΈ- Indianapolis, Indiana, United States Scroll for more (43 remaining)University of Alabama at Birmingham Comprehensive Cancer CenterπΊπΈBirmingham, Alabama, United States
